clinical development News
-
How to Get a Promotion in Clinical Development
In today’s highly competitive CRO job market, many qualified clinical team managers (CTMs) are vying for a small number of available clinical project management (CPM) positions. You could want that promotion for more exposure, monetary benefits, or because you’re tired of being in the same spot. But how do you make yourself stand out to get that promotion? In this ...
By Brio Group
-
How to Expand your Network in the Clinical Development Industry
As a clinical development professional, you know that building and maintaining relationships is key to success. Whether you are looking to move up within your current organization or make a lateral move to another company, expanding your network can help you achieve your goals. Here are a few tips on how to expand your network in the clinical development industry. 1. Get ...
By Brio Group
-
SurgiMab is an Entrepreneur Sponsor of the first Boston-Paris Biotechnology Summit
SurgiMab is an Entrepreneur Sponsor of the first Boston-Paris Biotechnology Summit and as such, we will present our latest clinical developments during the Entrepreneurs Forum. The Boston-Paris Biotechnology Summit is a novel catalyst event aiming to provide facilitative leadership for talents in both cities in order to foster energies and synergies, to spark new projects and to generate funding ...
By SurgiMab
-
Investor Webinar Presentation ShareCafe Small Cap “Hidden Gems” Webinar
Vice President of Clinical Development, Dougal Thring provided an overview of the Company’s peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. To see video, please click ...
-
Puzzle Medical announces partnership with MMC Medical for clinical developments
Puzzle Medical is delighted to announce our partnership with MMC Medical International Services for Puzzle Medical Devices' upcoming clinical developments. MMC is committed to its clients' clinical trials from protocol and trial design through the entire cycle of execution and study publications. Sharing nearly 30 years of industry and broad clinical experience MMC takes pride in supporting the ...
-
Showcase
Primary Results of Onawa (Solti-1802) Trial: A Window Of Opportunity Trial Of Onapristone In Postmenopausal Women With Progesterone Receptor-Positive/Her2-Negative Early Breast Cancer
PGR is an estrogen-responsive gene and progesterone receptor (PR) expression, evaluated by immunohistochemistry (IHC), is used as a clinical biomarker of estrogen signaling and estrogen receptor (ER) functionality.1 Despite the well-studied role of PGR as mitogen and independent ER activator, anti-progestins for the treatment of BC have been poorly tested. While limited success for ...
-
Transactions with warrants of series TO 1 in Curasight A/S made by managerial employees and their closely associated persons
Curasight A/S (“Curasight” or “the Company”). In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Curasight made by managerial employees and their closely associated persons. The Company’s managerial employees and their closely associated persons ...
By Curasight
-
Nova discovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development
Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jinko®, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline. Novadiscovery is committed to working with ...
-
Micron successfully completes feasibility study with top-10 pharmaceutical partner
ATLANTA, October 2, 2018 – Micron Biomedical, Inc. (Micron) recently completed a feasibility study with one of its commercial partners, a top-10 pharmaceutical company. The study consisted of developing a dissolving microneedle patch with specific design attributes to meet the partner’s unique delivery requirements and to assess the microneedle patch in in-vitro and in-vivo ...
-
TikoMed and IQVIA announce a strategic collaboration for the development of TIKOMED’s lead drug platform candidate ILB®
Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed’s lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration will support TikoMed’s clinical ...
By TIKOMED AB
-
Six Signs your Clinical Development Leadership is Failing
Efficient leadership plays a huge role in bringing a clinical trial to fruition. Pharmaceutical companies are not immune to making mistakes and facing failures. Lack of funding, safety issues, and patient dropouts are some of the struggles clinical development teams face. Some problems you as a leader may face may not always be in your control, e.g., lack of funding. Other ...
By Brio Group
-
ABK Biomedical Inc. Raises $30M USD in Series B Financing
ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a $30 million USD Series B financing. The round is co-led by F-Prime Capital and Varian Medical Systems. ABK Biomedical will use the funding for continued focused product development of its Eye90 microspheres™, which are designed for ...
-
FB2001 (Bofutrelvir) Phase II/III Clinical Trial Protocol Approved by NMPA
Frontier Biotech (stock code: 688221.SH) announced that the Phase II/III clinical study protocol of FB2001 (generic name: Bofutrelvir) is approved by the Center for Drug Evaluation, NMPA. The study is a worldwide multi-center, randomized, double-blind and placebo-controlled Phase II/III trial to evaluate the safety and efficacy of Bufutrelvir for hospitalized Covid-19 patients. Frontier Biotech ...
-
Adiposs starts clinical development of its flagship product ImageBAT
Adiposs SA, a Geneva-based biotech company developing medical imaging products, has successfully launched its phase 1 clinical trial on August 10, with the dosing of the first human subjects with ImageBATTM, its first-in-class product for brown fat imaging. Adiposs has initiated the clinical development of its flagship imaging product, ImageBATTM. The primary objective of the IBT001 phase 1 ...
By Adiposs
-
Novadiscovery announces new clinical simulation collaboration with Takeda
Novadiscovery (“NOVA”), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a new collaboration with “Takeda Pharmaceutical Company Limited (“Takeda”) aimed at incorporating clinical simulation technology on virtual ...
-
Clinical Trial Phase I “Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects” completed.
tiakis Biotech AG (formerly Proteo Biotech AG) has attained another milestone in its Pulmonary Arterial Hypertension (PAH) development program by receiving the final clinical phase 1 trial report demonstrating the very good safety profile of Tiprelestat (no severe adverse occurred). tiakis’s research partners and investigators at Stanford University School of Medicine, Dr. Marlene ...
-
Vestech works with Urucu to establish clinical trials
Urucu, a Brazilian natural therapy, has been launched in Australia as a skin moisturizer. Vestech is assisting IPS, the makers of Urucu, with developing a clinical trial strategy to assess the validity of a number of therapeutic claims made for this compound in ...
-
Vybion New Drug Webinar for Huntington`s Patients
Vybion (NY) conducted a webinar, sponsored by the Huntington's Disease Society of America (HSDA), for patients and caregivers on a new Gene Therapy drug called INT41. The company CEO described this new drug class called Intrabodies and how INT41 works in Huntington's Disease along with clinical development plans. The company believes that Intrabodies can achieve both the specificity and safety of ...
By Vybion
-
Atelerix appoints new CEO to lead its growing business and entry into cell therapy markets
Atelerix Ltd (Atelerix) announces the appointment of a new CEO as the company accelerates its growth programme. Over the last four years, the company has been led by co-founder and CEO, Mick McLean, as it developed its products and started commercialisation of its innovative cell encapsulation technology. Mick is now stepping back for personal reasons but will continue supporting the company as a ...
By Atelerix Ltd
-
Nicolas Sitchon, Ceo Of S1 Biopharma, To Present At Bio-Europe 2015 Conference
NEW YORK, Nov. 2, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men, today announced that Nicolas Sitchon, CEO of S1 Biopharma, will present at the BIO-Europe 2015 Conference on Tuesday, November 3, 2015 at the International Congress Center in Munich, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you